medium impactSAMHSA Fundingdata_releaseFederal

Release of the 2024 National Survey on Drug Use and Health: Leveraging the Latest Substance Use and Mental Health Data to Make America Healthy Again

July 28, 2025Source: SAMHSA
40
Relevance score
Tangential

Impact on your practice

This data release is important for understanding population trends but doesn't directly change practice operations. It may influence future funding allocations and policy priorities that affect therapists indirectly.

Key facts

1

2024 National Survey on Drug Use and Health released with latest epidemiological data

2

Provides updated prevalence rates for mental health and substance use conditions

3

Data informs federal funding priorities and policy decisions

Therapy Companion analysis

The 2024 NSDUH data signals a significant shift in your patient population and referral patterns over the next 12-24 months. Nearly 50 million Americans (16.8% of the population) meet diagnostic criteria for substance use disorder, while 61.5 million adults report any mental illness—these are your core market demographics. However, the treatment gap remains severe: only 19.3% of people needing substance use treatment actually receive it, while 52.1% of adults with any mental illness and 70.8% with serious mental illness do access mental health treatment. This means your practice will likely see increased demand for mental health services, particularly from younger adults (18-25 year-olds show the highest rates of anxiety, depression, and suicidal ideation). The data also reveals troubling upward trends in illicit drug use, marijuana use disorder, and hallucinogen use from 2021-2024, suggesting your caseload will increasingly include polysubstance use presentations requiring integrated treatment approaches. If you're not already equipped to screen for and address substance use alongside mental health conditions, you're missing a significant portion of your addressable market and potentially underserving existing clients. The adolescent mental health crisis is particularly acute: 18.8% of teens have moderate-to-severe anxiety, 15.4% have major depressive episodes, and 10.1% report serious suicidal thoughts. This data will directly influence insurance companies' prior authorization criteria, funding allocations to community mental health centers, and state Medicaid expansion decisions—all of which affect your reimbursement rates and patient volume within the next fiscal year.

Background

SAMHSA released this epidemiological snapshot to establish a data-driven foundation for the Trump Administration's 'Making America Healthy Again' (MAHA) agenda. The 2024 NSDUH is the first annual survey since 2020 with four consecutive years of comparable data (2021-2024), allowing trend analysis that was previously impossible. This timing is critical: federal agencies use NSDUH data to justify funding allocations, set policy priorities, and guide state-level implementation of mental health and substance use initiatives. The survey captures 73.6 million Americans reporting past-year illicit drug use, 50 million with substance use disorders, and 61.5 million with any mental illness—populations that directly translate into demand for your services. The emergence of novel synthetic opioids (fentanyl, nitazenes, xylazine) and increasing polysubstance use patterns mean the clinical complexity of your cases is rising, even as the overall prevalence of some traditional substances (tobacco, binge drinking) declines. This data release is being positioned as foundational evidence for reshaping federal mental health and substance use policy, which will cascade into changes in Medicaid reimbursement, grant funding priorities, and insurance coverage mandates within 6-18 months.

What you should do

1

Audit your current intake and assessment protocols to ensure you're systematically screening for both substance use and mental health conditions. The data shows 16% of Americans have substance use disorders while 23.4% have any mental illness—many clients present with both. If your intake doesn't include validated substance use screening (e.g., AUDIT, DAST-10), add it immediately to capture this comorbidity and justify treatment intensity to insurers.

2

Review your clinical documentation standards to explicitly address polysubstance use patterns and synthetic opioid exposure. Insurance companies will increasingly require evidence that you've assessed for fentanyl, xylazine, and benzodiazepine use given the epidemiological shift. Document your rationale for session frequency and modality based on NSDUH-informed risk stratification (e.g., young adults 18-25 show highest suicide risk and warrant more intensive monitoring).

3

Develop or strengthen referral partnerships with substance use disorder treatment providers and psychiatric prescribers. With only 19.3% of people needing substance use treatment actually receiving it, you'll encounter significant unmet need. Having warm handoff relationships with MAT providers, intensive outpatient programs, and psychiatrists will improve your treatment outcomes and reduce liability exposure when you identify untreated substance use disorders.

4

Prepare for increased demand from adolescents and young adults (ages 12-25) by Q3 2025. The data shows 33.2% of 18-25 year-olds have any mental illness, 14.5% have moderate-to-severe anxiety, and 15.9% have major depressive episodes. If you're not currently accepting adolescent clients or have limited pediatric capacity, consider expanding or establishing referral networks, as insurance companies and state Medicaid programs will prioritize funding for youth mental health services based on this data.

5

Monitor federal and state policy announcements over the next 6 months for changes to Medicaid reimbursement rates, prior authorization requirements, and substance use disorder coverage mandates. SAMHSA will use this data to justify funding shifts and policy changes. Subscribe to your state's Medicaid agency updates and your professional association's policy alerts to stay ahead of changes that will affect your revenue and operational requirements.

Notable excerpts

"Nearly 50 million Americans, 16.8% of people 12 years or older, met diagnostic criteria for a substance use disorder in the past year." This establishes the scale of untreated substance use in your potential patient population.

"In 2024, approximately 1 in 5 people (19.3%) who needed substance use treatment, actually received treatment in the past year." This 80% treatment gap underscores the market opportunity and clinical need for integrated mental health and substance use services.

"Among adults 18 years or older in 2024, 5.5% (14.3 million) reported serious thoughts of suicide in the past year, 1.8% (4.6 million) made a suicide plan, and 0.8% (2.2 million) attempted suicide." This suicide risk data will inform insurance prior authorization criteria and your documentation requirements for high-risk clients.

"Among adolescents aged 12 to 17, 15.4% (3.8 million) had a past year MDE and 11.3% (2.8 million) had a past year MDE with severe impairment in 2024." This adolescent depression prevalence will drive state and federal funding priorities toward youth mental health services.

View full source text
Date: July 28, 2025 Categories: Substance Use, Mental Health By: Art Kleinschmidt, Ph.D., M.B.A., Former Principal Deputy Assistant Secretary, Substance Abuse and Mental Health Services Administration Mental health, substance misuse, addiction, and their related health and social impacts such as overdose and suicide are dynamic and evolving. With the ready availability of illicitly made fentanyl and other potent synthetic opioids such as nitazenes, the emergence of substances like xylazine, medetomidine, and illicit benzodiazepines, and increasing polysubstance use, Americans face an illicit drug supply that is more toxic, unpredictable, and dangerous than ever. In addition, the proliferation of social media and other technology that is inundating America’s young people coupled with other social stressors in homes and communities across the Nation have contributed to declining mental health and well-being and rising rates of suicide in the past two decades. We know that mental health and substance use conditions are part of the chronic disease crisis plaguing our nation. Research shows that substance misuse and early health risk behaviors that take root during childhood and adolescence are closely linked to risk for chronic disease, substance use disorders, and mental health conditions later in life and contribute to a significant proportion of the health and social costs associated with chronic disease. By addressing mental health and substance misuse head-on through a comprehensive approach in partnership with states, communities, and tribes, we can help to achieve the Administration’s goal of Making America Health Again (MAHA) (PDF | 3.8 MB). As we embark on a bold new path to MAHA, having timely data to inform policy, program and practice are essential. For more than four decades, SAMHSA’s National Survey on Drug Use and Health (NSDUH) has been the federal government’s trusted source of information on substance use and mental health. Today, SAMHSA is releasing the 2024 NSDUH results which provide key insights into the latest trends and patterns of substance use and mental health among Americans. Of note, the 2024 NSDUH marks the first year since 2020 in which there are at least four years of comparable data for key NSDUH outcomes, enabling reporting of trends from 2021 to 2024 for many substance use and mental health measures. Linear tests of were conducted to determine whether an outcome of interest showed a statistically significant change from 2021 through 2024. Today’s release represents the earliest release of the annual NSDUH report, delivering on the Trump Administration’s promise of greater efficiency and transparency in data-driven policy making. Detailed below are some of the key findings from the 2024 NSDUH. Additional information, data, and resources can be found on the NSDUH webpage. Substance Use Among Americans 12 Years or Older Alcohol, nicotine and marijuana remain the most commonly used substances among Americans (Figure 1). In 2024, 134.3 million people aged 12 years or older reported using alcohol in the past month, followed by 48.0 million using tobacco products, 44.3 million using marijuana, and 27.7 million vaping nicotine. Figure 1. Number of Americans 12 Years or Older Reporting Past Month Use of Specific Substances, 2024 In 2024, approximately 1 in 4 Americans 12 years or older (73.6 million; 25.5%) reported illicit drug use in the past year (Figure 2). This included 64.2 million that reported past year use of marijuana, 10.4 million that used hallucinogens, 7.6 million misusing prescription opioids, 4.6 million misusing prescription tranquilizers or sedatives, and 4.3 million using cocaine. Figure 2. Number of Americans 12 Years or Older Reporting Use of Specific Illicit Drugs in the Past Year, 2024 In addition to past month and past year use, NSDUH captures the number of people in the U.S. who reported using specific drugs, alcohol, or nicotine for the first time in the past year (Figure 3). Nicotine vaping (5.4 million new initiates), alcohol use (4.2 million new initiates), and marijuana use (2.9 million new initiates) were most common substances. These annual numbers translate to approximately 14,800 new users of nicotine vaping, 11,500 new users of alcohol, 7,900 new users of marijuana each day in 2024. Figure 3. Past Year Initiates of Specific Substances Among People 12 Years or Older, 2024 Substance Use Disorders Among Americans 12 Years or Older In 2024, nearly 50 million Americans, 16.8% of people 12 years or older, met diagnostic criteria for a substance use disorder in the past year (Figure 4). Of these individuals, 27.9 had an alcohol use disorder, 28.2 million had a drug use disorder. About 1 in 6 people with a past year substance use disorder (16.0% or 7.7 million people) had both an alcohol use disorder and a drug use disorder in the past year. Marijuana use disorder was the most common drug use disorder (20.6 million), followed by opioid use disorder (4.8 million), and central nervous system stimulant use disorder (4.3 million) Figure 4. Past Year Substance Use Disorders Among People 12 Years or Older, 2024 Mental Health Among Adults 18 Years or Older For the first time in 2024, the NSDUH included the Generalized Anxiety Disorder (GAD-7) scale, a validated self-report measure to screen for and assess symptoms of GAD in the past two weeks. Among adults 18 years or older in the U.S., 7.4% had moderate or severe symptoms of anxiety and 14.3% had mild symptoms (Figure 5). Moderate to severe symptoms were more common among 18 to 25 year-olds (14.5%) compared to 26 to 49 year-olds (9.0%) and adults 50 years or older (3.9%). Figure 5. Generalized Anxiety Symptom Severity in the Past 2 Weeks Among Adults 18 Years Older, 2024 Among adults 18 years or older, 8.2% (21.4 million) had a past year major depressive episode (MDE). The percentage of adults aged 18 or older who had a past year MDE with severe impairment was 5.6% (14.7 million). As with generalized anxiety disorder symptoms, a larger percentage of adults 18 to 25 years old had MDE and MDE with severe impairment (15.9% and 11.5%, respectively) compared to adults aged 26 to 49 (10.0% and 7.0%) and 50 or older (4.4% and 2.6%). About 1 in 4 adults 18 years or older (23.4%; 61.5% million) had any mental illness (AMI) in the past year (Figure 6). The percentage of adults 18 to 25 years old with AMI was 33.2%, followed by 29.7% of adults 26 to 49 years old, and 15.2% of adults 50 or older. In 2024, 5.6% (14.6 million) of adults aged 18 years or older had serious mental illness (SMI) in the past year. Among adult age groups, SMI was highest among 18 to 25 year olds (9.4%), followed by 26 to 49 year olds (7.5%), and adults 50 years or older (2.8%). Figure 6. Percentage of Adults with Any Mental Illness and Serious Mental Illness in the Past Year, 2024 Suicidal Thoughts, Plans, and Attempts Among Adults Among adults 18 years or older in 2024, 5.5% (14.3 million) reported serious thoughts of suicide in the past year, 1.8% (4.6 million) made a suicide plan, and 0.8% (2.2 million attempted suicide (Figure 7). Figure 7. Suicidal Thoughts, Plans, and Attempts Among Adults, 2024 Adolescent Mental Health Among adolescents aged 12 to 17 in 2024, about 1 in 5 (18.8%; 4.9 million) had moderate or severe symptoms of GAD; about 1 in 4 adolescents (23.1%; 6.0 million) had mild symptoms (Figure 8). Figure 8. Generalized Anxiety Symptom Severity in the Past 2 Weeks Among Adolescents Aged 12 to 17 Years Old, 2024 Among adolescents aged 12 to 17, 15.4% (3.8 million) had a past year MDE and 11.3% (2.8 million) had a past year MDE with severe impairment in 2024 (Figure 9). Figure 9. Number of Percentage of Adolescents with Major Depressive Episode and Major Depressive Episode with Severe Impairment, 2024 In 2024, 2.6 million (10.1%) adolescents reported serious thoughts of suicide, 1.2 million (4.6%) made a suicide plan, and 700,000 (2.7%) attempted suicide (Figure 10). Figure 10. Suicidal Thoughts, Plans, and Attempts Among 12 to 17 Years Old, 2024 Treatment for Substance Use Disorders and Mental Illness In 2024, approximately 1 in 5 people (19.3%) who needed substance use treatment, actually received treatment in the past year. Treatment receipt was highest among adolescents aged 12 to 17 years (30.2% of those needing treatment reported receiving treatment in the past year), followed by those 26 years or older (20.5%) and those 18 to 25 years old (11.3%) (Figure 11). Figure 11. Receipt of Substance Use Treatment in the Past Year Among People Aged 12 or Older Who Needed Substance Use Treatment in the Past Year, 2024 In 2024, among adults with any mental illness and those with serious mental illness in the past year, most received mental health treatment in the past year. Overall, 52.1% of adults with any mental illness and 70.8% of those with serious mental illness reported receiving mental health treatment in the past year (Figure 12). Figure 12. Receipt of Mental Health Treatment in the Past Year Among People Adults 18 or Older with Any Mental Illness or Serious Mental Illness in the Past Year, 2024 Among the 3.8 million adolescents aged 12 to 17 in 2024 that had a past year major depressive episode, 60.6% (2.3 million) reported receiving mental health treatment in the past year (Figure 13). Figure 13. Types and Locations of Mental Health Treatment in the Past Year Among Adolescents Aged 12 to 17 with a Past Year Major Depressive Episode (MDE), 2024 In 2024, among adults 18 or older, 12.2% (31.7 million) perceived they ever had a problem with their use of drugs or alcohol. Among these adults, 74.3% (23.5 million) considered themselves to be in recovery or to have recovered from their drug or alcohol use problem. Similarly, 26.1% of adults (67.8 million) perceived they ever had a problem with their mental health. Among these adults, 66.9% (45.0 million) considered themselves to be in recovery or to have recovered from their mental health issue (Figure 14). Figure 14. Substance Use and Mental Health Recovery Among Adults 18 Years or Older, 2024 Key Substance Use and Mental Health Trends From 2021 to 2024 Among people 12 years or older, based on linear trend testing, most key outcome measures either decreased or remained stable between 2021 and 2024 (Figure 15). Figure 15. Key Substance Use and Mental Health Trends from 2021 to 2024 Using the 2024 NSDUH To Drive Policy, Program, and Practice Strategies The 2024 NSDUH identifies areas of progress in our work to address substance use and mental illness as well as key opportunities as we move forward our MAHA agenda and goals. On the progress front, we see from the NSDUH that the percentage of people 12 years or older reporting use of most substances either decreased or remained stable between 2021 and 2024, with decreases in past month use of tobacco, cigarettes, binge and heavy drinking as well as decreases in past year use of cocaine, misuse of prescription opioids, and past year alcohol use disorder. We also saw declines in a number of adolescent mental health measures between 2021 and 2024, including major depressive episode with and without severe impairment, co-occurring major depressive episode and substance use disorder, and all three measures of suicide – serious thoughts of suicide, suicide plans, and suicide attempts. In addition, the high percentage of American adults that report being in recovery – 74.3% of those who perceived they ever had a problem with their use of drugs or alcohol and 66.9% of those who perceived they ever had a problem with their mental health – is a statistic to highlight and to help spread hope about the power and healing of recovery. But the NSDUH also identifies trends heading in the wrong direction. This includes past year illicit drug use, marijuana use, and hallucinogen use and past year drug use disorder and marijuana use disorder. Among adults, we also saw that the percentage of people 18 or older that reported making a suicide plan increased between 2021 and 2024. Of note, the increases in past-year illicit drug use and past-year drug use disorders are largely driven by increases in marijuana use and marijuana use disorder among adults 26 years or older. Although marijuana use and use disorder trends remained stable among adolescents and young adults between 2021 and 2024, the increase in adult use is important to inform prevention and treatment activities given changing attitudes around marijuana use and the shifting state policy landscape which has increased risk for marijuana use and use disorder among young people, and enabled the ready availability of high-potency marijuana products linked to negative health impacts in communities across the country. A key pattern that has emerged in recent years is the prominence of vaping, especially among young people. In the 2024 NSDUH we find that among past month users of tobacco or nicotine products, 71.5% of 12 to 17 year-olds and 50.3% of 18 to 25 year-olds reported only vaping nicotine in contrast to 18.0% among adults 26 or older. For past month users of marijuana, 71.1% of 12 to 17 year-olds and 52.0% of 18 to 25 year-olds reported vaping marijuana compared to 33% among those 26 or older (Figure 16). Figure 16. Routes of Nicotine and Marijuana Use Among Past-Month Users of Each Substance, 2024 The NSDUH also highlights the substantial overlap between substance use and mental health. Although mental health and substance use funding and treatment systems have historically often been separate, the NSDUH clearly demonstrates that in reality, people with substance use disorders and those with mental health challenges often have co-occurring conditions. For both adults and adolescents with mental health challenges, the prevalence of substance use is higher compared to those without mental health challenges. As shown in Figure 17, whether it is adolescents with major depressive episode or moderate or severe anxiety symptoms, the prevalence of each substance use measure is significantly higher among those with mental health challenges. Figure 17. Prevalence of Substance Use Among Adolescents 12 to 17 by Mental Health Status, 2024 The same is true for adults with any mental illness and serious mental illness as well as adults with moderate or severe anxiety symptoms (Figure 18). Figure 18. Prevalence of Substance Use Among Adults 18 or Older by Mental Health Status, 2024 We see a similar pattern when we look at the overlap of substance use disorders and any mental illness and serious mental illness (Figure 19). Among the 61.5 million adults with any mental illness in the past year in 2024, 21.2 million (34.5%) also had a substance use disorder. Among the 14.6 million adults with serious mental illness in the past year in 2024, 6.9 million (47.3%) also had a substance use disorder. Among the 46.3 million adults with a substance use disorder in the past year in 2024, 45.8% had any mental illness and 14.9% had seri [Truncated]
Analysis by Therapy Companion AI policy engineConfidence: highAnalyzed: August 20, 2026

Policy changes drive denial patterns

Therapy Companion tracks both: the policy shifts on this page and the denial patterns hitting your claims.

Related policy changes

high72

STAT+: Trump administration quietly picks Timothy Westlake to lead mental health agency

SAMHSA leadership directly impacts federal funding streams, clinical guidance, and regulatory priorities that affect therapists nationwide. Westlake's background in addiction policy signals potential shifts in how SAMHSA allocates resources and develops clinical standards.

medium58

[OK] HB1911: Mental health; definitions; 988 Suicide and Crisis Lifeline System; administrative structure; evaluation; workforce retention; trust fund; telecommunication fee; maximization of federal funding; effective date.

This bill addresses the operational backbone of Oklahoma's 988 system with emphasis on workforce stability and federal funding leverage. For therapists, stable 988 infrastructure and workforce retention means more reliable crisis response for clients and potential partnership opportunities. The federal funding maximization language suggests the state is actively pursuing SAMHSA grants and other federal resources.

medium55

[OK] HB4092: 988 Mental Health Lifeline; terms; Department of Mental Health and Substance Abuse Services; suicide prevention and crisis service activities; performance and clinical standards; promulgation of rules; 988 Lifeline Revolving Fund; purpose; funding; enforcement; effective date.

While this bill primarily affects crisis centers and 988 infrastructure rather than direct therapy practice, it signals state investment in crisis services that may create referral pathways and reduce emergency department burden for therapists' clients. The funding mechanism and performance standards could influence how crisis services coordinate with outpatient mental health providers.

medium48

HHS clears 2 peer support programs for federal foster care funding

This expands federal funding pathways for peer support-based interventions in child welfare and family services. Therapists working in family-based treatment, substance use, or child welfare may see increased referrals or partnership opportunities as states adopt these programs, though direct reimbursement impact is limited.